190 results
8-K
EX-99.1
NOTV
Inotiv Inc
7 Feb 24
Inotiv Reports First Quarter Financial Results for Fiscal 2024 and Provides Business Update
4:14pm
FY 2024”) ended December 31, 2023.
Revenue by Segment
(in millions of USD)
Three months ended
December 31
change
(unaudited)
DSA (Discovery & Safety … %, in Discovery and Safety Assessment (“DSA”) revenue.
Consolidated net loss for Q1 FY 2024 was $15.8 million, or 11.7% of total revenue, compared
8-K
EX-99.1
NOTV
Inotiv Inc
11 Dec 23
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update
4:17pm
& Safety Assessment)
RMS (Research Models & Services)
Total
Management Commentary
Robert Leasure Jr., President and Chief Executive Officer … customer base in: Drug Discovery and Translational Science, Drug Development, Chemical Development, and Medical Device Development, including Safety
8-K
EX-99.1
9ouruhxe9s
10 Aug 23
Inotiv Reports Third Quarter Financial Results for Fiscal 2023 and Provides Business Update
4:11pm
8-K
EX-99.1
pmxx4ahqmnle9 1j1sn7
11 May 23
Inotiv, Inc. Announces Second Quarter Fiscal 2023 Financial Results
4:16pm
8-K
EX-99.1
xaqeh12
12 Dec 22
Inotiv, Inc. Provides Business Update and Select Preliminary Fiscal Year 2022 Financial Results
8:00am
8-K/A
EX-3.1
80yc2t1n2h
8 Nov 22
Amendments to Articles of Incorporation or Bylaws
5:27pm
8-K
EX-3.1
wo46glyzeva
7 Nov 22
Amendments to Articles of Incorporation or Bylaws
4:30pm
8-K
EX-99.1
wvwq0omna69h2
10 Aug 22
Inotiv, Inc. Announces Third Quarter Fiscal 2022 Financial Results
4:11pm
8-K
EX-99.1
8xhpu95w2lpqna2m qza
12 May 22
Inotiv, Inc. Announces Second Quarter Fiscal 2022 Financial Results
4:55pm
8-K
EX-99.1
9m31w
10 Feb 22
Inotiv, Inc. Announces First Quarter Fiscal 2022 Financial Results
4:12pm